BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 26269456)

  • 1. The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.
    Fionda C; Abruzzese MP; Zingoni A; Cecere F; Vulpis E; Peruzzi G; Soriani A; Molfetta R; Paolini R; Ricciardi MR; Petrucci MT; Santoni A; Cippitelli M
    Oncotarget; 2015 Sep; 6(27):23609-30. PubMed ID: 26269456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.
    Petillo S; Capuano C; Molfetta R; Fionda C; Mekhloufi A; Pighi C; Antonangeli F; Zingoni A; Soriani A; Petrucci MT; Galandrini R; Paolini R; Santoni A; Cippitelli M
    Cell Death Dis; 2021 Sep; 12(9):836. PubMed ID: 34482362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
    Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
    J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
    Patil A; Manzano M; Gottwein E
    Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct Roles for Human Cytomegalovirus Immediate Early Proteins IE1 and IE2 in the Transcriptional Regulation of MICA and PVR/CD155 Expression.
    Pignoloni B; Fionda C; Dell'Oste V; Luganini A; Cippitelli M; Zingoni A; Landolfo S; Gribaudo G; Santoni A; Cerboni C
    J Immunol; 2016 Nov; 197(10):4066-4078. PubMed ID: 27733551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
    Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
    Front Immunol; 2020; 11():40. PubMed ID: 32082316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
    Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
    Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
    Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
    Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
    Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
    Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1.
    Soriani A; Iannitto ML; Ricci B; Fionda C; Malgarini G; Morrone S; Peruzzi G; Ricciardi MR; Petrucci MT; Cippitelli M; Santoni A
    J Immunol; 2014 Jul; 193(2):950-60. PubMed ID: 24913980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
    Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK
    Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Aiolos and Ikaros in the Antitumor and Immunomodulatory Activity of IMiDs in Multiple Myeloma: Better to Lose Than to Find Them.
    Cippitelli M; Stabile H; Kosta A; Petillo S; Gismondi A; Santoni A; Fionda C
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
    Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
    Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
    Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
    Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
    El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
    Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
    Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M
    J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation.
    Fionda C; Abruzzese MP; Zingoni A; Soriani A; Ricci B; Molfetta R; Paolini R; Santoni A; Cippitelli M
    BMC Cancer; 2015 Jan; 15():17. PubMed ID: 25609078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma.
    Zingoni A; Vulpis E; Cecere F; Amendola MG; Fuerst D; Saribekyan T; Achour A; Sandalova T; Nardone I; Peri A; Soriani A; Fionda C; Mariggiò E; Petrucci MT; Ricciardi MR; Mytilineos J; Cippitelli M; Cerboni C; Santoni A
    Front Immunol; 2018; 9():926. PubMed ID: 29765374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
    Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
    Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3.
    Fionda C; Malgarini G; Soriani A; Zingoni A; Cecere F; Iannitto ML; Ricciardi MR; Federico V; Petrucci MT; Santoni A; Cippitelli M
    J Immunol; 2013 Jun; 190(12):6662-72. PubMed ID: 23686482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.